Scientists at Oxford University may have developed a test that is more sensitive to diagnosing mesothelioma.
The researchers were seeking to find a method to distinguish mesothelioma as a cause of pleural effusion, the build-up of fluid in the pleural cavity surrounding the lungs. Pleural effusion has many causes, but more than 90% of people with mesothelioma have this symptom.
The study looked at levels of the protein mesothelin - which is released in high quantities in the pleural fluid of most patients with mesothelioma.
It was found that quantities of the protein were much greater in patients with mesothelioma than in those with secondary lung cancers, and 10 times higher than those with benign conditions.
It is hoped that this technique will allow doctors to diagnose mesothelioma at an earlier stage, using fewer invasive procedures. This will mean doctors can intervene at an earlier stage to treat the cancer, and claims for compensation for mesothelioma can be instigated earlier.
The study is due to be published in the American Journal of Respiratory and Critical Care Medicine at the start of September.
Contact us on freephone 0800 358 3848
Or start your claim online.
"The group is praised for its commitment to 'demystifying the legal process' while this is a firm for which the client has always been a priority"
Fieldfisher has successfully been recognised as an "Occupation and Asbestos Disease Specialists" Fieldfisher are now recognised as assessors
Charities we support
Sarah Wolf comments on worrying reports regarding asbestos use in the USA
The Fieldfisher mesothelioma team is closely monitoring the furore that has broken out in the US following reports that the US Environmental Protection Agency (EPA) has paved the way for the use of new products containing asbestos.
The legacy of asbestos
Asbestos mining and manufacturing companies in Wittenoom, Western Australia have left a lasting legacy of the dangers of asbestos.
Peter Williams reacts to multi-billion dollar judgement against Johnson & Johnson in talc claims
American pharmaceutical giant Johnson & Johnson was last week ordered to pay $4.69 billion to 22 women who have suffered ovarian cancer allegedly as a result of using talcum powder contaminated with asbestos.
Fieldfisher out in support of Action Mesothelioma Day 2018
On Friday 6 July 2018, Fieldfisher's Asbestos Team was out in support of Action Mesothelioma Day.